Anderson KE, Stamler D, Davis MD, et al. Deutetrabenazine for treatment of involuntary movements in patients with tardive dyskinesia (AIM-TD): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Psychiatry. 2017;4:595-604.
Austedo^® [package insert]. North Wales, PA: Teva Pharmaceuticals USA, Inc. 2017.
Bhidayasiri R, Jitkritsadakul O, Friedman JH, et al. Updating the recommendations for treatment of tardive syndromes: a systematic review of new evidence and practical treatment algorithm. J Neurol Sci. 2018;389:67-75.
Carbon M, Hsieh CH, Kane JM, et al. Tardive dyskinesia prevalence in the period of second-generation antipsychotic use: a meta-analysis. J Clin Psychiatry. 2017;78(3):e264-e278.
Caroff S, Cutler A, Tanner C, et al. RE-KINECT, a real-world, prospective tardive dyskinesia screening study: an evaluation of baseline characteristics in older patients. Am J Geriatr Psychiatry. 2019;27:S176-S178
Caroff SN, Ungvari GS, Cunningham Owens DG. Historical perspectives on tardive dyskinesia. J. Neurol. Sci. 2018;389:4-9.
Citrome L, Duresne R, Dyrud JM. Tardive dyskinesia: minimizing risk and improving outcomes in schizophrenia and other disorders. Am J Manag Care. 2007;13(Suppl):1-12.
Citrome L. Clinical management of tardive dyskinesia: five steps to success. J Neurol Sci. 2017;383:199-204.
Citrome L. Deutetrabenazine for tardive dyskinesia: A systematic review of the efficacy and safety profile for this newly approved novel medication—What is the number needed to treat, number needed to harm and likelihood to be helped or harmed? Int J Clin Pract. 2017;71:e13030.
ClinicalTrials.gov. Reducing Involuntary Movements in Tardive Dyskinesia (RIM-TD). https://clinicaltrials.gov/ct2/show/NCT02198794. Accessed June 21, 2019.
Correll CU, Cutler AJ, Kane JM, et al. Characterizing treatment effects of valbenazine for tardive dyskinesia: additional results from the KINECT 3 study. J Clin Psychiatry. 2019;80:18m12278.
Correll CU, Schenk EM. Tardive dyskinesia and new antipsychotics. Curr Opin Psychiatry. 2008;21:151-156.
Fernandez HH, Factor SA, Hauser RA, et al. Randomized controlled trial of deutetrabenazine for tardive dyskinesia: the ARM-TD study. Neurology. 2017;88:2003-2010.
Ganzini L, Casey DE, Hoffman WF, et al. Tardive dyskinesia and diabetes mellitus. Psychopharmacol Bull. 1992;28:281-286.
Guy W (ed). ECDEU Assessment Manual for Psychopharmacology, revised ed. DHEW Publ No ADM 76-338. Washington, DC, US Department of Health, Education, and Welfare, 1976.
Hauser RA, Factor SA, Marder SR, et al. KINECT 3: a phase 3 randomized, double-blind, placebo-controlled trial of valbenazine for tardive dyskinesia. Am J Psychiatry. 2017;174:476-484.
Ingrezza^® [package insert]. San Diego, CA: Neurocrine Biosciences, Inc. 2017.
Jankelowitz SK. Treatment of neuroleptic-induced tardive dyskinesia. Neuropsychiatr Dis Treat. 2013;9:1371-1380.
Jeste DV, Wyatt RJ. Changing epidemiology of tardive dyskinesia: an overview. Am J Psychiatry. 1981;138:297-309.
Lerner V, Miodownik C. Motor symptoms of schizophrenia: is tardive dyskinesia a symptom or side effect? A modern treatment. Curr Psychiatry Rep. 2011;13(4):295-304.
McEvoy J, Park T, Schilling T, et al. The burden of tardive dyskinesia secondary to antipsychotic medication use among patients with mental disorders. Curr Med Res Opin. 2019;35:1205-1214.
Miller DD, Caroff SN, Davis SM, et al. Extrapyramidal side-effects of antipsychotics in a randomised trial. Br J Psychiatry. 2008;193:279-288.
Saltz BL, Woerner MG, Kane JM, et al. Prospective study of tardive dyskinesia incidence in the elderly. JAMA. 1991;266:2402-2406.
Schonecker M. Paroxysmal dyskinesia as the effect of megaphen. Nervenarzt.1957;28:550-553.
Schooler NR, Kane JM. Research diagnoses for tardive dyskinesia. Arch Gen Psychiatry. 1982;39:486-487
Singer C, Comella C, Farahmand K, et al. Assessing the effectiveness of valbenazine in the treatment of tardive dyskinesia as determined by the AIMS and PGIC: results from the KINECT 4 trial. Mov Disord. 2018;33(suppl 2).
Solmi M, Pigato G, Kane JM, et al. Treatment of tardive dyskinesia with VMAT-2 inhibitors: a systematic review and meta-analysis of randomized controlled trials. Drug Des Devel Ther. 2018;12:1215-1238.
Ward KM, Citrome L. Antipsychotic-related movement disorders: drug-induced parkinsonism vs. tardive dyskinesia – key differences in pathophysiology and clinical management. Neurol Ther. 2018;7:233-248.
Woerner MG, Alvir JM, Saltz BL, et al. Prospective study of tardive dyskinesia in the elderly: rates and risk factors. Am J Psychiatry. 1998;155:1521-1528.
Woerner MG, Saltz BL, Kane JM, et al. Diabetes and development of tardive dyskinesia. Am J Psychiatry. 1993;150:966-968.

As an organization accredited by the ACCME, Medscape, LLC, requires everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest.

Medscape, LLC, encourages Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration, at first mention and where appropriate in the content.

Moderator

Andrew J. Cutler, MD

Clinical Professor of Psychiatry
SUNY Upstate Medical University
Syracuse, New York

Disclosures

Disclosure: Andrew J. Cutler, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Alkermes, Inc.; Allergan, Inc.; Avanir Pharmaceuticals, Inc.; Gedeon Richter; Intra-Cellular Therapies; Lundbeck, Inc.; Neurocrine Biosciences, Inc.; Novartis Pharmaceuticals Corporation; Otsuka America Pharmaceutical, Inc.; Sunovion Pharmaceuticals Inc.; Takeda Pharmaceuticals North America, Inc.; Teva Pharmaceuticals USA
Served as a speaker or a member of a speakers bureau for: Alkermes, Inc.; Allergan, Inc.; Avanir Pharmaceuticals, Inc.; Lundbeck, Inc.; Neurocrine Biosciences, Inc.; Otsuka America Pharmaceutical, Inc.; Sunovion Pharmaceuticals Inc.; Takeda Pharmaceuticals North America, Inc.
Received grants for clinical research from: Alkermes, Inc.; Allergan, Inc.; Avanir Pharmaceuticals, Inc.; Intra-Cellular Therapies; Lundbeck, Inc.; Neurocrine Biosciences, Inc.; Novartis Pharmaceuticals Corporation; Otsuka America Pharmaceutical, Inc.; Sunovion Pharmaceuticals Inc.; Takeda Pharmaceuticals North America, Inc.

Panelists

Kapil D. Sethi, MD, FRCP

Professor Emeritus of Neurology
Augusta University
Augusta, Georgia

Disclosures

Disclosure: Kapil D. Sethi, MD, FRCP, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Adamas Pharmaceuticals, Inc.; Neurocrine Biosciences, Inc.; Sunovion Pharmaceuticals Inc.
Received grants for clinical research from: Acorda Therapeutics; Kyowa Kirin Pharmaceutical Development, Inc.; Sunovion Pharmaceuticals Inc.; US WorldMeds, LLC.

Dawn Vanderhoef, PhD, DNP, PMHNP-BC

Assistant Professor
Academic Director
Vanderbilt University School of Nursing
Nashville, Tennessee

Disclosures

Disclosure: Dawn Vanderhoef, PhD, DNP, PMHNP-BC, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Neurocrine Biosciences, Inc.
Served as a speaker or a member of a speakers bureau for: Neurocrine Biosciences, Inc.

Editors

Anjali Mehra, MD

Lead Medical Education Director, Medscape, LLC

Disclosures

Disclosure: Anjali Mehra, MD, has disclosed no relevant financial relationships.

Yoji Yamaguchi, MA

Associate Scientific Content Manager, Medscape, LLC

Disclosures

Disclosure: Yoji Yamaguchi, MA, has disclosed no relevant financial relationships.

CME/CE Reviewer

Esther Nyarko, PharmD

Associate Clinical CME Director, Medscape, LLC

Disclosures

Disclosure: Esther Nyarko, PharmD, has disclosed no relevant financial relationships.

Nurse Planner

Amy Bernard, MS, BSN, RN-BC, CHCP

Lead Nurse Planner, Medscape, LLC

Disclosures

Disclosure: Amy Bernard, MS, BSN, RN-BC, CHCP, has disclosed no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has disclosed no relevant financial relationships.

CME / ABIM MOC / CE

Expert Insights in Diagnosis and Management of Common Drug-Induced Movement Disorders

Authors: Andrew J. Cutler, MD; Kapil D. Sethi, MD, FRCP; Dawn Vanderhoef, PhD, DNP, PMHNP-BC
CME / ABIM MOC / CE Released: 6/26/2019
THIS ACTIVITY HAS EXPIRED
Valid for credit through: 6/26/2020

Start Activity

Target Audience and Goal Statement

This activity is intended for psychiatrists, neurologists, primary care physicians, nurses, nurse practitioners, and physician assistants.

The goal of this activity is to provide clinicians with greater knowledge and confidence in accurately and promptly diagnosing tardive dyskinesia (TD), making appropriate treatment selections, and incorporating team-based management of the patient.

Upon completion of this activity, participants will:

Have increased knowledge regarding the
- Nuances associated with making a differential diagnosis of TD
- Prevalence, incidence, and impact of TD on patients
- Accurate diagnosis of patients with TD
Have greater competence related to
- Designing a management strategy for patients with TD
Demonstrate greater confidence in their ability to
- Understand the role of the team in recognizing and diagnosing TD

Disclosures

Moderator

Andrew J. Cutler, MD

Clinical Professor of Psychiatry
SUNY Upstate Medical University
Syracuse, New York

Disclosures

Disclosure: Andrew J. Cutler, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Alkermes, Inc.; Allergan, Inc.; Avanir Pharmaceuticals, Inc.; Gedeon Richter; Intra-Cellular Therapies; Lundbeck, Inc.; Neurocrine Biosciences, Inc.; Novartis Pharmaceuticals Corporation; Otsuka America Pharmaceutical, Inc.; Sunovion Pharmaceuticals Inc.; Takeda Pharmaceuticals North America, Inc.; Teva Pharmaceuticals USA
Served as a speaker or a member of a speakers bureau for: Alkermes, Inc.; Allergan, Inc.; Avanir Pharmaceuticals, Inc.; Lundbeck, Inc.; Neurocrine Biosciences, Inc.; Otsuka America Pharmaceutical, Inc.; Sunovion Pharmaceuticals Inc.; Takeda Pharmaceuticals North America, Inc.
Received grants for clinical research from: Alkermes, Inc.; Allergan, Inc.; Avanir Pharmaceuticals, Inc.; Intra-Cellular Therapies; Lundbeck, Inc.; Neurocrine Biosciences, Inc.; Novartis Pharmaceuticals Corporation; Otsuka America Pharmaceutical, Inc.; Sunovion Pharmaceuticals Inc.; Takeda Pharmaceuticals North America, Inc.

Panelists

Kapil D. Sethi, MD, FRCP

Professor Emeritus of Neurology
Augusta University
Augusta, Georgia

Disclosures

Disclosure: Kapil D. Sethi, MD, FRCP, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Adamas Pharmaceuticals, Inc.; Neurocrine Biosciences, Inc.; Sunovion Pharmaceuticals Inc.
Received grants for clinical research from: Acorda Therapeutics; Kyowa Kirin Pharmaceutical Development, Inc.; Sunovion Pharmaceuticals Inc.; US WorldMeds, LLC.

Dawn Vanderhoef, PhD, DNP, PMHNP-BC

Assistant Professor
Academic Director
Vanderbilt University School of Nursing
Nashville, Tennessee

Disclosures

Disclosure: Dawn Vanderhoef, PhD, DNP, PMHNP-BC, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Neurocrine Biosciences, Inc.
Served as a speaker or a member of a speakers bureau for: Neurocrine Biosciences, Inc.

Editors

Anjali Mehra, MD

Lead Medical Education Director, Medscape, LLC

Disclosures

Disclosure: Anjali Mehra, MD, has disclosed no relevant financial relationships.

Yoji Yamaguchi, MA

Associate Scientific Content Manager, Medscape, LLC

Disclosures

Disclosure: Yoji Yamaguchi, MA, has disclosed no relevant financial relationships.

CME/CE Reviewer

Esther Nyarko, PharmD

Associate Clinical CME Director, Medscape, LLC

Disclosures

Disclosure: Esther Nyarko, PharmD, has disclosed no relevant financial relationships.

Nurse Planner

Amy Bernard, MS, BSN, RN-BC, CHCP

Lead Nurse Planner, Medscape, LLC

Disclosures

Disclosure: Amy Bernard, MS, BSN, RN-BC, CHCP, has disclosed no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has disclosed no relevant financial relationships.

Accreditation Statements

In support of improving patient care, Medscape LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

For Physician Assistants

Medscape, LLC has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.50 AAPA Category 1 CME credits. Approval is valid until June 26, 2020. PAs should only claim credit commensurate with the extent of their participation.

For Physicians

Medscape, LLC designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Medscape, LLC staff have disclosed that they have no relevant financial relationships.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.50 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

Contact This Provider

For Nurses

Awarded 0.50 contact hour(s) of continuing nursing education for RNs and APNs; 0.25 contact hours are in the area of pharmacology.

Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]

Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.

Follow these steps to earn CME/CE credit*:

Read the target audience, learning objectives, and author disclosures.
Study the educational content online or printed out.
Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

From Medscape Education Psychiatry & Mental Health

CME / ABIM MOC / CE

Expert Insights in Diagnosis and Management of Common Drug-Induced Movement Disorders

Authors: Andrew J. Cutler, MD; Kapil D. Sethi, MD, FRCP; Dawn Vanderhoef, PhD, DNP, PMHNP-BCFaculty and Disclosures

THIS ACTIVITY HAS EXPIRED

CME / ABIM MOC / CE Released: 6/26/2019

Valid for credit through: 6/26/2020

processing....

Educational Impact Challenge

Before you begin this activity, please assess your clinical knowledge by completing this brief survey. Answering these questions again after the activity will allow you to see what you learned and to compare your answers with those of your peers.

Page 1 of 4

CME / ABIM MOC / CE Information Download Slides

Activity Transcript

Print
Like Tweet

Disclaimer

The educational activity presented above may involve simulated, case-based scenarios. The patients depicted in these scenarios are fictitious and no association with any actual patient, whether living or deceased, is intended or should be inferred. The material presented here does not necessarily reflect the views of Medscape, LLC, or any individuals or commercial entities that support companies that support educational programming on medscape.org. These materials may include discussion of therapeutic products that have not been approved by the US Food and Drug Administration, off-label uses of approved products, or data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal. Readers should verify all information and data before treating patients or employing any therapies described in this or any educational activity. A qualified healthcare professional should be consulted before using any therapeutic product discussed herein.

References

Faculty and Disclosures

Moderator

Andrew J. Cutler, MD

Panelists

Kapil D. Sethi, MD, FRCP

Dawn Vanderhoef, PhD, DNP, PMHNP-BC

Editors

Anjali Mehra, MD

Yoji Yamaguchi, MA

CME/CE Reviewer

Esther Nyarko, PharmD

Nurse Planner

Amy Bernard, MS, BSN, RN-BC, CHCP

CME / ABIM MOC / CE

Expert Insights in Diagnosis and Management of Common Drug-Induced Movement Disorders

Target Audience and Goal Statement

Disclosures

Moderator

Andrew J. Cutler, MD

Panelists

Kapil D. Sethi, MD, FRCP

Dawn Vanderhoef, PhD, DNP, PMHNP-BC

Editors

Anjali Mehra, MD

Yoji Yamaguchi, MA

CME/CE Reviewer

Esther Nyarko, PharmD

Nurse Planner

Amy Bernard, MS, BSN, RN-BC, CHCP

Accreditation Statements

For Physician Assistants

For Physicians

For Nurses

Instructions for Participation and Credit

Expert Insights in Diagnosis and Management of Common Drug-Induced Movement Disorders

Educational Impact Challenge